Cognitive impairment as a target for pharmacological treatment in schizophrenia

Schizophr Res. 1995 Sep;17(1):123-9. doi: 10.1016/0920-9964(95)00037-m.
No abstract available

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Chronic Disease
  • Cognition Disorders / diagnosis
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / psychology
  • Humans
  • Neuropsychological Tests
  • Nootropic Agents / adverse effects
  • Nootropic Agents / therapeutic use*
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*

Substances

  • Antipsychotic Agents
  • Nootropic Agents